We are live on !
Find out more
Stempoint Capital Portfolio holdings
AUM
$560M
Turnover
64.34%
1-Year Est. Return
146.87%
This Fund
S&P 500
This Quarter Est. Return
+25.39%
1 Year Est. Return
+146.87%
3 Year Est. Return
+725.67%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$375M
AUM Growth
–
Cap. Flow
+$287M
Cap. Flow % of AUM
Cap. Flow %
76.64%
Top 10 Holdings %
Top 10 Hldgs %
39.49%
Holding
67
New
67
Increased
–
Reduced
–
Closed
–
Avg Time Held
Equity + Options
0
years
Top 10 Avg Time Held
Equity + Options
0
years
Top 20 Avg Time Held
Equity + Options
0
years
Avg Time Held Equity only
0
years
Top 10 Avg Time Held Equity only
0
years
Top 20 Avg Time Held Equity only
0
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Roivant Sciences
ROIV
|
+$21.1M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$16.8M |
| 3 |
Arcellx
ACLX
|
+$14.1M |
| 4 |
Immunovant
IMVT
|
+$11.8M |
| 5 |
Merus
MRUS
|
+$11.7M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.59% |
| 2 | Miscellaneous | 8.41% |
Similar funds
AAM
MHR
Stempoint Capital's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for Stempoint Capital, which disclosed 67 positions worth $375M. Its ten largest holdings account for 39% of the portfolio.
Its largest position is Roivant Sciences: 2,169,116 shares worth $24.4M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, followed by Miscellaneous.
- Stempoint Capital's largest Q4 2023 buy was Roivant Sciences: 2,169,116 shares worth $24.4M.
- Stempoint Capital's ten largest holdings make up 39% of its $375M portfolio in Q4 2023.
- Stempoint Capital disclosed 67 positions in Q4 2023, its first 13F filing on record.
Based on Stempoint Capital's 13F filing for Q4 2023, filed 13 Feb 2024.